Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates
Summary
EPO published patent application EP3349796A1 for ImmunoGen, Inc., covering therapeutic combinations of anti-FOLR1 immunoconjugates for cancer treatment. The A1 publication indicates the application has passed EPO's search examination and is now publicly available. The patent covers compositions including the novel ADC candidate targeting folate receptor alpha (FOLR1), a validated cancer antigen, along with combination therapies using cytotoxins and additional anticancer agents.
What changed
EPO published patent application EP3349796A1 for ImmunoGen, Inc., covering anti-FOLR1 immunoconjugate compositions and therapeutic combinations for cancer treatment. The patent claims priority to multiple A61K, C07K, and A61P classifications spanning antibody-drug conjugate (ADC) technology, cytotoxic payloads including platinum compounds, and combination regimens with anticancer agents.
For pharmaceutical and biotechnology companies developing FOLR1-targeted therapies, this patent establishes ImmunoGen's intellectual property position in Europe for ADC-based cancer treatments. Competitors pursuing similar FOLR1-ADC programs or combination approaches should conduct freedom-to-operate analyses and consider licensing negotiations to mitigate infringement risk in designated EP patent states.
What to do next
- Monitor patent for grant confirmation
- Assess Freedom-to-Operate for FOLR1-targeted therapies in Europe
- Evaluate patent claims for licensing opportunities
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
Publication EP3349796A1 Kind: A1 Apr 08, 2026
Applicants
ImmunoGen, Inc.
Inventors
PONTE, Jose, PINKAS, Jan, RUIZ-SOTO, Rodrigo R.
IPC Classifications
A61K 39/395 20060101AFI20250213BHEP C07K 16/28 20060101ALI20250213BHEP C07K 16/30 20060101ALI20250213BHEP C07K 16/46 20060101ALI20250213BHEP A61K 45/06 20060101ALI20250213BHEP A61K 31/555 20060101ALI20250213BHEP A61K 31/704 20060101ALI20250213BHEP A61K 33/24 20060101ALI20250213BHEP C07K 16/22 20060101ALI20250213BHEP A61K 39/00 20060101ALI20250213BHEP A61K 47/68 20170101ALI20250213BHEP A61P 35/00 20060101ALI20250213BHEP A61K 33/243 20190101ALI20250213BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.